About bridgebio oncology therapeutics inc - BBOT
Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.
BBOT At a Glance
Bridgebio Oncology Therapeutics, Inc.
256 East Grand Avenue
South San Francisco, California 94080
| Phone | 1-650-405-4770 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -134,044,000.00 | |
| Sector | Health Technology | Employees | 92 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BBOT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.436 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.226 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.084 |
BBOT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,457,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BBOT Liquidity
| Current Ratio | 12.34 |
| Quick Ratio | 12.34 |
| Cash Ratio | 12.142 |
BBOT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -41.661 |
| Return on Equity | -44.695 |
| Return on Total Capital | -32.389 |
| Return on Invested Capital | -44.529 |
BBOT Capital Structure
| Total Debt to Total Equity | 0.673 |
| Total Debt to Total Capital | 0.668 |
| Total Debt to Total Assets | 0.616 |
| Long-Term Debt to Equity | 0.546 |
| Long-Term Debt to Total Capital | 0.542 |